Last reviewed · How we verify
NCT03492710
Study of Immune Globulin Intravenous (Human) GC5101F in Subjects With Primary Humoral Immunodeficiency
Phase 3 trial testing Immunoglobulin in Primary Immune Deficiency Disorder. Withdrawn.
30 April 2019
Quick facts
| Lead sponsor | Green Cross Corporation |
|---|---|
| Phase | Phase 3 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 30 April 2019 |
| Primary completion | 30 April 2019 |
| Estimated completion | 30 April 2019 |
Drugs / interventions tested
- Immunoglobulin — full drug profile →
Conditions studied
- Primary Immune Deficiency Disorder — all drugs for Primary Immune Deficiency Disorder →
Sponsor
Green Cross Corporation — full company profile →
Who can join
Adults 24 Months to 203 Months, any sex, with Primary Immune Deficiency Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To assess the safety, efficacy, and pharmacokinetics of IGIV-SN in pediatric subjects with primary immunodeficiency humoral diseases (PHID)
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03492710
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Immunoglobulin
Trials testing the same drug.
- NCT04589299 — Subcutaneous Immunoglobulin in De-novo CIDP (SIDEC) · Phase 4 · recruiting
- NCT04381936 — Randomised Evaluation of COVID-19 Therapy · Phase 3 · recruiting
- NCT01561053 — A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease · Phase 2, PHASE3 · completed
Other recruiting trials for Primary Immune Deficiency Disorder
Currently open trials in the same condition.
- NCT03266653 — EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection · Phase 2 · recruiting
- NCT04197596 — Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs) · Phase 1, PHASE2 · recruiting
- NCT04232085 — Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failu · Phase 2 · recruiting
- NCT03266640 — Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV) · Phase 2 · recruiting
- NCT03266627 — Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection · Phase 2 · recruiting
Other Green Cross Corporation trials
Trials by the same sponsor.
- NCT01624532 — A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109 · Phase 2 · completed
- NCT04555148 — COVIDIG (COVID-19 Hyper-ImmunoGlobulin) · Phase 2 · completed
- NCT04175522 — Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis: · Phase 2 · completed
- NCT03947138 — A Study of GC3107(BCG Vaccine) in Healthy Infants · Phase 3 · completed
- NCT04003844 — Study of Combined Therapy IVIG-SN 10% and Acetylsalicylic Acid in Kawasaki Disease · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03492710 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Green Cross Corporation
- Last refreshed: 7 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03492710.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing